Skip to Main Content

Once again, lawmakers have introduced legislation to end the tax breaks that drug makers can take for advertising their medicines to consumers, a move that effectively becomes part of a wider package of bills  Democrats are devising rein in the pharmaceutical industry.

The latest attempt comes from Sen. Jeanne Shaheen (D-N.H.), who argues that drug makers are spending too much to market high-priced medicines at a time of growing anger over the cost of prescription drugs. The legislation, called the End Taxpayer Subsidies for Drug Ads Act, would amend the Internal Revenue Code to disallow deductions for such ads.


“A major side effect of big pharma’s enormous ad spending is that it drives up prescription drug costs and rips off taxpayers in the process,” Shaheen said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.